FY2024 EPS Estimates for NeuroBo Pharmaceuticals, Inc. Cut by Analyst (NASDAQ:NRBO)

NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) – Analysts at Zacks Small Cap cut their FY2024 earnings per share estimates for shares of NeuroBo Pharmaceuticals in a research note issued on Tuesday, April 23rd. Zacks Small Cap analyst D. Bautz now anticipates that the company will earn ($3.83) per share for the year, down from their previous estimate of ($2.83). The consensus estimate for NeuroBo Pharmaceuticals’ current full-year earnings is ($3.00) per share. Zacks Small Cap also issued estimates for NeuroBo Pharmaceuticals’ FY2025 earnings at ($2.59) EPS.

NeuroBo Pharmaceuticals Stock Performance

Shares of NRBO stock opened at $3.06 on Friday. NeuroBo Pharmaceuticals has a 12 month low of $2.89 and a 12 month high of $6.75. The company’s fifty day moving average price is $4.47 and its 200-day moving average price is $3.97.

NeuroBo Pharmaceuticals Company Profile

NeuroBo Pharmaceuticals, Inc, a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy for both NASH and T2D; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP1R/GCGR dual agonist for the treatment of NASH and obesity.